Trevena CEO to Present at the 9th Annual JMP Securities Healthcare Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 11:00 a.m. EDT at The Westin Grand Central in New York City.

To access a live audio webcast of the presentation, please visit the “Investors” section at www.trevenainc.com. The webcast will be archived for 30 days.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate-to-severe acute pain intravenously, and TRV734 to treat moderate-to-severe acute and chronic pain orally. Trevena also is advancing additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.

Investor:
Trevena, Inc.
Jonathan Violin, 610-354-8840 x231
Director of investor relations
jviolin@trevenainc.com
or
Argot Partners
Andrea Rabney, 212-600-1902
President and chief executive officer
andrea@argotpartners.com
or
Media:
Argot Partners
Eliza Schleifstein, 917-763-8106
eliza@argotpartners.com

Source: Trevena, Inc.

Released June 18, 2014